Cat.No. GAU 017-01B
Mouse monoclonal antibody, biotinylated
Recognizes an epitope that is present on human C3, C3a and C3a (desArg).
Does not cross-react with C4a or C5a.
GAU 017-01 recognizes different epitopes on the 9 kDa C3a than GAU 013-16. No reaction is seen with a synthetic octapeptide representing the C3a C-terminal.
100 µL, 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Complement C3a is an anaphylatoxin of 77 amino acid residues released by the action of the C3 convertases on the N-terminal of the alpha chain of C3. It is rapidly inactivated by serum carboxypeptidase N which removes the C-terminal arginine residue generating C3a (desArg).
GAU 017-01 can be used as a biotinylated detection antibody in sandwich ELISA with GAU 013-16 capture antibody (1-5). Does not inhibit the biological activity of C3a (1).
|The calibration curve of a sandwich assay for C3a/C3a(desArg) using GAU 013-16 as the capture antibody and GAU 017-01B as the biotinylated detection antibody.|
GAU 017-01B was used in IHC on human appendix section.
|IHC staining of human appendix section. Plasma of veins stained strongly. Dilution: 1:30|
1. Nezlin R, Freywald A, Oppermann M (1993) Proteins separeted from human IgG molecules. Mol. Immunol. 30:935-940.
2. Oppermann M, Liebmann F, Götze O. (1987) Purification and quantification of human C3a anaphylatoxin using monoclonal antibodies. Complement 4:205-206
3. Oppermann M, Haubitz M, Quintin E, Götze O (1988) Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and Factor B. Klin Wochenschr 66:857-864.
4. Khodoun M, Strait R, Orekov T, Hogan S, Karasuyama H, Herbert DBR, Köhl J, Finkelman FD (2009) Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol 123:342-351.
5. Thomas SN, van der Vlies AJ, O’Neil CP, Reddy ST, Yu SS, Giorgio TD, Swartz MA, Hubbell JA (2011) Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials 32: 2194-2203.